Italia markets closed

JNJ May 2024 165.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,02000,0000 (0,00%)
Alla chiusura: 10:33AM EDT
Schermo intero
Chiusura precedente0,0200
Aperto0,0200
Denaro0,0000
Domanda2,1300
Prezzo d'esercizio165,00
Scadenza2024-05-31
Min-Max giorno0,0200 - 0,0200
Contratto - Min-MaxN/D
Volume16
Open InterestN/D
  • GlobeNewswire

    Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

    According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA